R Horton et al.
General pharmacology, 19(3), 403-405 (1988-01-01)
1. Oral administration of the GABA transaminase inhibitor ethanolamine-O-sulphate (EOS, 5 mg/ml in drinking water) to rats for 14 days suppressed food intake by 24%, but reduced weight gain by over 35%. 2. Thus, feed efficiency (g gain/MJ eaten) was...
D V Coscina et al.
International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 16(6), 425-433 (1992-06-01)
To explore recent suggestions that genetically obese Zucker rats show less anorexia when brain gamma-aminobutyric acid (GABA) is elevated, obese vs. lean littermates received 100, 50 and 0 micrograms of the GABA-transaminase inhibitor, ethanolamine-O-sulfate (EOS), intra-cisternally in a longitudinal design...
A E Herbison et al.
Journal of neurochemistry, 55(5), 1617-1623 (1990-11-01)
The characteristics of gamma-aminobutyric acid (GABA) release as monitored by microdialysis have been investigated in the chloral hydrate anaesthetised rat. The high outflow of GABA following insertion of the microdialysis probe (membrane 2 mm in length, 0.5 mm in diameter)...
GABA-mimetic compounds block haloperidol-induced hyperprolactinemia in rats.
L Debeljuk et al.
Advances in biochemical psychopharmacology, 42, 139-144 (1986-01-01)
H Hodges et al.
Physiology & behavior, 41(3), 257-264 (1987-01-01)
Studies have shown that benzodiazepines (BZs) both disrupt discrimination and increase resistance to punishment. Using a delayed response task, we provide evidence that effects of BZs on discrimination cannot be fully explained by deficits in either short or long term...